Expert opinion on optimal testosterone control in prostate cancer

European Urology, Supplements

Volumn 4, Issue 8, 2005, Pages 37-41

  Zlotta, Alex ^a   Debruyne, Frans M J ^b,c  

^a ERASME HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Appropriate testosterone suppression; Expert consensus meeting; Expert consultation; Guidelines; LHRH agonists; Prostate cancer; Testosterone; Testosterone rise

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CASTRATION; HUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TESTIS; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE;

EID: 26444562945     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.08.005     Document Type: Article

References (6)

1. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 7 1988 165 170
2. W.P. Jordan, C.E. Blackard, and D.P. Byar Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma South Med J 70 1977 1411 1413
3. Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl. 2005;(4):30-6.
4. M.G. Oefelein, and M.I. Resnick Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62 2 2003 207 213
5. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 6 2000 1021 1024
6. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 4 2005 14 19